Swiss pharmaceutical company Novartis heads to the Indian Supreme Court today in New Delhi, in a final bid to undermine a key public health safeguard in Indian patent law specifically designed to prevent drug companies from abusive patenting practices that keep medicine prices high. If successful, the move would have a devastating impact on access to essential medicines across the developing world, according to the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF), which relies on affordable generic drugs produced in India to carry out its work in 68 countries.
